ilmscore | Prediction Details
"you can basically understand the impact companies will Will face once generic revision comes off from the base the extent of earnings detorsion you can you can very well gauge"
By Groww | April 24, 2025 | Pending
From video
Sensex, Nifty rally pauses; FMCG & realty stocks fall | Tariff-proofing your pharma portfolio 00:22:57 - 00:23:07
Interpreted Prediction
Companies with high exposure to generic Revlimid (e.g., Natco Pharma, Dr. Reddy's) are predicted to face significant earnings deterioration upon its generic revision expiry in January 2026.

Prediction Details

Topic
Pharma Sector (Generic Revlimid Impact)

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.